Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1996 2
1998 1
1999 1
2002 1
2006 1
2008 1
2009 1
2010 1
2011 2
2012 2
2013 1
2014 1
2015 2
2016 1
2017 1
2018 2
2019 2
2020 7
2021 2
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study.
Spunt SL, Million L, Chi YY, Anderson J, Tian J, Hibbitts E, Coffin C, McCarville MB, Randall RL, Parham DM, Black JO, Kao SC, Hayes-Jordan A, Wolden S, Laurie F, Speights R, Kawashima E, Skapek SX, Meyer W, Pappo AS, Hawkins DS. Spunt SL, et al. Lancet Oncol. 2020 Jan;21(1):145-161. doi: 10.1016/S1470-2045(19)30672-2. Epub 2019 Nov 27. Lancet Oncol. 2020. PMID: 31786124 Free PMC article.
BACKGROUND: Tumour grade, tumour size, resection potential, and extent of disease affect outcome in paediatric non-rhabdomyosarcoma soft-tissue sarcoma (NRSTS), but no risk stratification systems exist and the standard of care is poorly defined. ...At a media …
BACKGROUND: Tumour grade, tumour size, resection potential, and extent of disease affect outcome in paediatric non-rhabdomyosarcoma s …
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.
Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, Kelley RK, Ros W, Italiano A, Nakagawa K, Rugo HS, de Braud F, Varga AI, Hansen A, Wang H, Krishnan S, Norwood KG, Doi T. Piha-Paul SA, et al. Int J Cancer. 2020 Oct 15;147(8):2190-2198. doi: 10.1002/ijc.33013. Epub 2020 May 2. Int J Cancer. 2020. PMID: 32359091 Free article.
Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). ...Grade 3 to 5 treatment-related adverse events occurred in 13 …
Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpresser …
Localized Synovial Sarcoma: A Population-Based Analysis of Treatment Patterns and Survival.
Singh A, Thorpe S, Keegan T, Maguire F, Malogolowkin M, Abrahão R, Spunt S, Carr-Asher J, Alvarez E. Singh A, et al. J Adolesc Young Adult Oncol. 2023 Oct;12(5):634-643. doi: 10.1089/jayao.2022.0143. Epub 2023 Apr 27. J Adolesc Young Adult Oncol. 2023. PMID: 37104039
Purpose: Synovial sarcoma (SS) is a rare, high-grade soft tissue tumor that requires multidisciplinary and multimodal care with surgery, radiotherapy, and chemotherapy. ...Among AYAs, treatment at NCI-COG-designated facilities was associated with recei …
Purpose: Synovial sarcoma (SS) is a rare, high-grade soft tissue tumor that requires multidisciplinary and multimodal care …
Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA.
Anderson P, Ghisoli M, Crompton BD, Klega KS, Wexler LH, Slotkin EK, Stanbery L, Manning L, Wallraven G, Manley M, Horvath S, Bognar E, Nemunaitis J. Anderson P, et al. Clin Cancer Res. 2023 May 1;29(9):1689-1697. doi: 10.1158/1078-0432.CCR-22-2292. Clin Cancer Res. 2023. PMID: 36780200 Free PMC article.
PURPOSE: Treatment options for recurrent or refractory Ewing's sarcoma (ES) are limited. Vigil is a novel autologous tumor cell therapy expressing bi-shRNA furin/GMCSF plasmid, which previously demonstrated monotherapy activity in advanced ES. ...We observed two par …
PURPOSE: Treatment options for recurrent or refractory Ewing's sarcoma (ES) are limited. Vigil is a novel autologous tumor cell th …
Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients With Cancer.
Phillips GS, Freret ME, Friedman DN, Trelles S, Kukoyi O, Freites-Martinez A, Unger RH, Disa JJ, Wexler LH, Tinkle CL, Mechalakos JG, Dusza SW, Beal K, Wolden SL, Lacouture ME. Phillips GS, et al. JAMA Dermatol. 2020 Sep 1;156(9):963-972. doi: 10.1001/jamadermatol.2020.2127. JAMA Dermatol. 2020. PMID: 32756880 Free PMC article.
OBJECTIVE: To characterize pRIA in patients with primary central nervous system (CNS) tumors or head and neck sarcoma. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study of patients from January 1, 2011, to January 30, 2019, was conducted at 2 large ter …
OBJECTIVE: To characterize pRIA in patients with primary central nervous system (CNS) tumors or head and neck sarcoma. DESIGN, SETTIN …
Treatment Approaches and Outcomes for Primary Mediastinal Sarcoma: Analysis of 976 Patients.
Engelhardt KE, DeCamp MM, Yang AD, Bilimoria KY, Odell DD. Engelhardt KE, et al. Ann Thorac Surg. 2018 Aug;106(2):333-339. doi: 10.1016/j.athoracsur.2018.03.068. Epub 2018 May 2. Ann Thorac Surg. 2018. PMID: 29729268 Free PMC article.
BACKGROUND: Primary mediastinal sarcomas are rare and deadly. Our objective was to describe the clinicopathological features, treatment strategies, and overall survival outcomes for a contemporary cohort of patients diagnosed with primary mediastinal sarcoma in the …
BACKGROUND: Primary mediastinal sarcomas are rare and deadly. Our objective was to describe the clinicopathological features, treatme …
ESR1 hotspot mutations in endometrial stromal sarcoma with high-grade transformation and endocrine treatment.
Dessources K, Miller KM, Kertowidjojo E, Da Cruz Paula A, Zou Y, Selenica P, da Silva EM, Benayed R, Ashley CW, Abu-Rustum NR, Dogan S, Soslow RA, Hensley ML, Weigelt B, Chiang S. Dessources K, et al. Mod Pathol. 2022 Jul;35(7):972-978. doi: 10.1038/s41379-021-01003-5. Epub 2021 Dec 27. Mod Pathol. 2022. PMID: 34961764 Free PMC article.
High-grade endometrial stromal sarcomas (HGESSs) are more aggressive and have higher rates of resistance to endocrine therapy than low-grade endometrial stromal sarcomas (LGESSs). ...Furthermore, our data suggest that genetic analyses may be per …
High-grade endometrial stromal sarcomas (HGESSs) are more aggressive and have higher rates of resistance to endocrine thera …
Early treatment-related neutropenia predicts response to palbociclib.
McAndrew NP, Dickson MA, Clark AS, Troxel AB, O'Hara MH, Colameco C, Gallager M, Gramlich K, Zafman K, Vaughn D, Schwartz GK, O'Dwyer PJ, DeMichele A. McAndrew NP, et al. Br J Cancer. 2020 Sep;123(6):912-918. doi: 10.1038/s41416-020-0967-7. Epub 2020 Jul 9. Br J Cancer. 2020. PMID: 32641862 Free PMC article.
Grade 3-4 neutropenia was significantly associated with prolonged PFS in the non-breast cohort (HR 0.57, 95% CI 0.38-0.85, p = 0.006) but not in the breast cohort (HR 0.87, 95% CI 0.51-1.47, p = 0.596). ...CLINICAL TRIALS REGISTRATION INFORMATION: Basket Trial: NCT01037790 …
Grade 3-4 neutropenia was significantly associated with prolonged PFS in the non-breast cohort (HR 0.57, 95% CI 0.38-0.85, p = 0.006) …
Executive summary of the American Radium Society Appropriate Use Criteria for management of uterine carcinosarcoma.
Elshaikh MA, Modh A, Jhingran A, Biagioli MC, Coleman RL, Gaffney DK, Harkenrider MM, Heskett K, Jolly S, Kidd E, Lee LJ, Li L, Portelance L, Sherertz T, Venkatessan AM, Wahl AO, Yashar CM, Small W Jr. Elshaikh MA, et al. Gynecol Oncol. 2020 Aug;158(2):460-466. doi: 10.1016/j.ygyno.2020.04.683. Epub 2020 May 29. Gynecol Oncol. 2020. PMID: 32475772 Review.
Patients with UCS appear to benefit from adjuvant multimodality therapy to reduce the chance of tumor recurrence with the potential to improve overall survival. CONCLUSION: Women diagnosed with uterine UCS should undergo complete surgical staging. Adjuvant multimodality …
Patients with UCS appear to benefit from adjuvant multimodality therapy to reduce the chance of tumor recurrence with the potential t …
Disparities in adjuvant treatment of high-grade endometrial cancer in the Medicare population.
Corey L, Cote ML, Ruterbusch JJ, Vezina A, Winer I. Corey L, et al. Am J Obstet Gynecol. 2022 Apr;226(4):541.e1-541.e13. doi: 10.1016/j.ajog.2021.10.031. Epub 2021 Nov 1. Am J Obstet Gynecol. 2022. PMID: 34736911 Free PMC article.
OBJECTIVE: This study aimed to examine patterns of adjuvant therapy and survival for non-Hispanic Black women vs non-Hispanic White women and Hispanic women who have undergone surgery for high-grade endometrial cancer in the Medicare population. ...This study sugges …
OBJECTIVE: This study aimed to examine patterns of adjuvant therapy and survival for non-Hispanic Black women vs non-Hispanic White w …
32 results